We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Vaxcyte Inc
1 watching
Current Price
$46.17
$-0.72
(-1.54%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
2,796.64M
52-Week High
49.31
52-Week Low
16.86
Average Volume
0.35M
Dividend Yield
--
P/E Ratio
--
Market Capitalization2,796.64M52-Week High49.3152-Week Low16.86Average Volume0.35MDividend Yield--P/E Ratio--What does the Vaxcyte Inc do?
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Read More
How much money does Vaxcyte Inc make?
News & Events about Vaxcyte Inc.
Globe Newswire
25days ago
-- Breakthrough Therapy Designation for 24-Valent Investigational Pneumococcal Conjugate Vaccine Candidate Based on Positive Topline Proof-of-Concept Data Results in Adults Aged 18-64 That Suggest Potential Best-in-Class Profile -- -- Topline Safety, Tolerability and Immunogenicity Data from VAX-24 ...
Globe Newswire
3 months ago
SAN CARLOS, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of ...
PR Newswire
3 months ago
Thinking about buying stock in Vaxcyte, Frontline, Avis Budget Group, ServiceNow, or Wolfspeed? Thinking about buying stock in Vaxcyte, Frontline, Avis Budget Group, ServiceNow, or Wolfspeed? PR Newswire NEW YORK, Oct. 24, 2022 NEW YORK, Oct. 24, 2022 /PRNewswire/ -- InvestorsObserverissues...
Zolmax
3 months ago
Vaxcyte, Inc. (NASDAQ:PCVX Get Rating) COO Jim Wassil sold 2,800 shares of Vaxcyte stock in a transaction that occurred on Monday, October 17th. The stock was sold at an average price of $25.72, for a total transaction of $72,016.00. Following the sale, the chief operating officer now owns 42,344 ...
Frequently Asked Questions
Frequently Asked Questions
What is Vaxcyte Inc share price today?
Can Indians buy Vaxcyte Inc shares?
How can I buy Vaxcyte Inc shares from India?
Can Fractional shares of Vaxcyte Inc be purchased?
What are the documents required to start investing in Vaxcyte Inc stocks?
What is today’s traded volume of Vaxcyte Inc?
What is today’s market capitalisation of Vaxcyte Inc?
What is the 52-Week High and Low Range of Vaxcyte Inc?
What percentage is Vaxcyte Inc down from its 52-Week High?
What percentage is Vaxcyte Inc up from its 52-Week Low?
Current Price
$46.17
$-0.72
(-1.54%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.